Leukemia drug repurposed to fight resistant lung cancer

NCT ID NCT06225427

Recruiting now Disease control Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests gilteritinib, a drug already approved for leukemia, in 30 people with stage IV ALK-positive non-small cell lung cancer that has stopped responding to other treatments. The main goal is to find the safest dose and check for side effects. Researchers hope the drug can overcome resistance that often develops to standard ALK-targeted therapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gilteritinib
What this could lead to: If it works, this could offer a new treatment option for people with ALK-positive lung cancer whose current drugs have stopped working.
What could go wrong: This is a very early Phase I trial with only 30 people, so it is not yet known if gilteritinib will be effective or safe for lung cancer. Side effects could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG NON-SMALL CELL CARCINOMA STAGE IV LUNG CANCER AJCC V8

Contacts and locations

Locations

Cedars-Sinai Medical Center
NOT_YET_RECRUITING

Los Angeles, California, 90048, United States
Georgetown University
NOT_YET_RECRUITING

Washington D.C., District of Columbia, 20007, United States
University of Michigan Comprehensive Cancer Center
RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.